Overview

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Status:
Unknown status
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
To assess the primary effects and safety of Anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3.
Phase:
Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd